Enveric Biosciences Reports Dual 5-HTA Pathway Engagement for Lead Candidate EB-003.

Enveric Biosciences reported new data from BRET assays demonstrating that its lead candidate, EB-003, activates both Gq-and ß-arrestin-mediated signaling downstream of the 5-HT A receptor. This suggests therapeutic benefit can arise from either mechanism. EB-003 shows a modest preference toward ß-arrestin signaling and is being advanced through IND-enabling studies. The company continues to progress toward clinical development.